Bank Julius Baer & Co. Ltd, Zurich Ionis Pharmaceuticals Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$42.03 - $53.55 $217,715 - $277,389	5,180 Added 57.24%	14,230 $616,000
Q4 2023 May 16, 2024	SELL	$43.39 - $51.63 $41,220 - $49,048	-950 Reduced 9.5%	9,050 $457,000
Q4 2023 May 16, 2024	SELL	$43.39 - $51.63 $183,539 - $218,394	-4,230 Reduced 29.73%	10,000 $505,000
Q4 2023 Feb 02, 2024	BUY	$43.39 - $51.63 $392,679 - $467,251	9,050 New	9,050 $458,000
Q3 2021 Nov 12, 2021	SELL	$33.54 - $40.55 $9.69 Million - $11.7 Million	-288,844 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$34.54 - $47.25 $31,673 - $43,328	917 Added 0.32%	288,844 $11.5 Million
Q1 2021 May 10, 2021	BUY	$42.51 - $63.78 $12.2 Million - $18.4 Million	287,927 New	287,927 $12.9 Million
Q3 2020 Nov 10, 2020	SELL	$47.45 - $62.95 $9.3 Million - $12.3 Million	-195,993 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$46.85 - $61.05 $3.66 Million - $4.77 Million	-78,088 Reduced 28.49%	195,993 $11.5 Million
Q1 2020 May 13, 2020	BUY	$41.6 - $63.4 $11.4 Million - $17.4 Million	274,081 New	274,081 $12.9 Million

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.